Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ginseng gets COO labeling under USDA rule

This article was originally published in The Tan Sheet

Executive Summary

Ginseng root will receive country-of-origin labeling at the retail level under a final rule the Department of Agriculture published in the Jan. 15 Federal Register. Under the rule, effective March 16, USDA will make funding available to develop an automated review tracking system and conduct audits of the retail supply chain, the agency says in a Jan. 12 release. American Botanical Council Executive Director Mark Blumenthal said in an e-mail that COO labeling "addresses a serious problem in the American ginseng-producing community," since roots grown in Southeast Asia are often imported by the U.S. as fraudulent "Wisconsin-grown" ginseng. The USDA rule incorporates the aim of the Ginseng Harvest Labeling Act of 2007, introduced by Wisconsin's congressional delegation to protect growers in the state (1"The Tan Sheet" Aug. 13, 2007, p. 7)

You may also be interested in...



Wisconsin Delegation Proposes “Country Of Harvest” On Raw Ginseng Labels

Members of the congressional delegation from Wisconsin, where about 95 percent of U.S. ginseng is cultivated, have proposed amending agricultural manufacturing regulations to require labels for raw ginseng roots indicate the country of harvest

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102535

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel